Yiou Health reported on June 12,Yaoshi (Suzhou) Medical Technology Co., Ltd. ("Yesight") completed a multi-million yuan Series A round of financing. This round of financing was led by Delian Capital, with continued investment from existing shareholder Beijing Qiwo Boxing Management Consulting Co., Ltd., and WinX Capital serving as the exclusive financial advisor.After this round of financing, Yesight will further accelerate the clinical registration and production of its ultra-widefield confocal laser scanning ophthalmoscope (Scanning Laser Ophthalmoscope, SLO) product, as well as the research and development of multiple innovative ophthalmic optical devices, continuing to lead the industry. Yesight has completed two rounds of financing in less than a year, fully demonstrating the capital market's recognition of the company.
Yesight is an innovative ophthalmic optical device platform technology enterprise that integrates R&D, production, sales, and AI big data research. The company's headquarters is located in Suzhou, China, with a research institute in Japan. The current team focuses on the development of SLO ultra-wide-field confocal laser scanning retinal camera technology for ophthalmic diagnosis, with product specifications reaching world-leading levels. Based on confocal laser scanning imaging technology and integrated circuit technology, the company has developed an internationally advanced SLO ultra-wide-field confocal laser scanning ophthalmoscope, as well as multiple innovative diagnostic and screening devices for ophthalmic diseases.
Taking the "fundus camera," the most important equipment in routine ophthalmic examinations, as the entry point,
Break the Monopoly of Imported High-End Ophthalmic Equipment
Ophthalmology: The Golden Track in the Capital Market
According to data from the National Health Commission and the National Bureau of Statistics, China has a large number of ophthalmic patients. The number of people with refractive problems alone has exceeded 800 million, and with the increasing incidence of cataracts, glaucoma, macular degeneration, and other conditions, the number of people suffering from eye diseases in China has surpassed 1 billion.As the most important equipment for routine ophthalmic examinations and preliminary diagnosis, fundus cameras will serve nearly all patients with ophthalmic diseases in China and have broad market potential in the future.
Fundus Camera Application Scenarios,Data source: 2020 National Vision Health Report
A leading ophthalmic optical equipment platform in China,
Develop the First Clinically Verified SLO Ultra-Widefield Confocal Laser Scanning Ophthalmoscope Made in China
Traditional fundus cameras have clinical technical bottlenecks such as small imaging field of view (about 45°), high minimum pupil requirement (above 3.3mm), poor LED optical penetration (unable to capture deep fundus), and unclear fundus vascular imaging, which can easily lead to missed diagnoses of peripheral lesions in clinical practice. To address these pain points, the ultra-widefield confocal laser scanning ophthalmoscope was developed. Compared with traditional fundus cameras, ultra-widefield devices provide clearer images and a broader field of view, making them the optimal tool for fundus diagnosis.
However, at present, the Chinese fundus camera market is still dominated by traditional optical fundus camera technology, mostly occupied by overseas international brands such as Japan's Topcon and Japan's Canon. As ophthalmologists increasingly demand wider imaging range and higher clarity of fundus images, the demand for ultra-widefield confocal fundus cameras in China is steadily growing. However, these devices are heavily reliant on imports from overseas, and their prices are expensive, with the current terminal hospital admission price generally exceeding 1.5 million yuan.
Yesight has developed the world's first SLO ultra-widefield confocal laser scanning ophthalmoscope featuring electronic scanning mirror technology, with fully independent intellectual property rights. It boasts characteristics such as wide-field fundus imaging, no need for pupil dilation, strong penetration through refractive media, fast imaging speed, and clear images, effectively addressing the clinical pain points of traditional optical fundus cameras. This breakthrough is expected to end the overseas monopoly in high-end SLO ultra-widefield confocal laser scanning ophthalmoscope technology.
Yesight's SLO is also one of the first batch of SLO ultra-widefield confocal products to undergo clinical validation in China.Currently, this product has initiated clinical trials in China, led by top domestic ophthalmic hospitals and top industry Principal Investigators (PIs), with all performance indicators rivaling imported products. From a data perspective, Yesight's single field of view achieves an ultra-wide angle of 168 degrees (optical incident angle of 113 degrees). Moreover, its multi-spectral confocal laser scanning imaging technology fully covers the diagnostic area of all 10 layers of retinal tissue at the back of the eye, providing wider, more comprehensive, and clearer fundus color images and clinical data.
Originating from a top Japanese optical technology background team,
Global Perspective and Cooperation Network
The Yesight medical team is composed of domestic and international experts and engineering technicians with advanced technical expertise. The team’s strong engineering R&D capabilities, combined with its international perspective and experience, as well as its deep understanding of clinical needs, enable the company to continuously develop and produce innovative ophthalmic medical devices. This positions the company to provide high-quality solutions for a wide range of ophthalmic patients and medical staff in China and overseas.
Currently, the company has launched exclusive strategic cooperation with a well-known Japanese technology listed company to jointly layout the ophthalmic market in China and overseas. In addition, it has signed a sales framework agreement for some products with a top three Japanese eyewear store group company.The product technology has been recognized by large overseas enterprises, laying a solid foundation for the internationalization of the company's products.
Yesight CEO Hai Zhou Wu stated:Thank You to Delian Capital and Old Shareholder Beijing Qiwo Boxing Management Consulting Co., Ltd. for Their Trust and Support. Yesight has Always Been Committed to Achieving a Society of Universal Eye Health Through the Early Diagnosis and Treatment of Eye Diseases. Since Its Establishment in 2020, the Company Has Developed Rapidly. The Team, Based on Decades of Advanced Ophthalmic Optical Technology Accumulated in Japan, Has Created the SLO Ultra-Widefield Confocal Laser Scanning Ophthalmoscope, Breaking the Monopoly of Imported High-End Ophthalmic Equipment. The Demand for Ophthalmology in China Continues to Grow, and Domestic Substitutes Are Gaining Momentum. In the Future, the Company Will Continue to Develop High-End Ophthalmic Disease Screening and Diagnostic Equipment That Is Clear in Image Quality, Easy to Operate, and Stable in Quality, Covering More Than 90% of Ophthalmic Disease Diagnosis Areas Such as Fundus, Anterior Segment, Optic Nerve, and Refraction. We Hope to Promote Industry Development with Advanced Ophthalmic Equipment Technology.
Vice President of Delian Capital, Li Zhongbao, stated:Fundus diseases are one of the leading causes of irreversible blindness, and fundus cameras are widely used for fundus examinations in clinical settings. Due to the limitations of traditional optical fundus cameras, such as a narrow field of view and poor penetration, a new type of ultra-widefield laser fundus camera has rapidly gained popularity in China in recent years, with the market largely dominated by imported brands. The Yesight team, originating from Japan's top ophthalmic companies, has leveraged its deep technical expertise and extensive industry experience to develop the world’s first SLO ultra-widefield confocal laser scanning ophthalmoscope based on an electronic scanning mirror. This innovative device combines high performance with low cost. It is the first domestically produced laser-based SLO to undergo formal clinical trials and directly compete head-to-head with imported brands, earning recognition from many leading principal investigators (PIs) in the field of fundus diseases. We look forward to the company’s product launching soon, contributing to the screening of eye diseases in China.
Zhang Lan, Partner of Beijing Qiwo Boxing Management Consulting Co., Ltd., statedOphthalmology is one of the key investment areas for Boxing Capital. Boxing Capital continues to have confidence in Yesight's innovative R&D capabilities and global resources, and is pleased to have the opportunity to support Yesight with early-stage investments and to increase investment in this round. We look forward to the company launching multiple ophthalmic devices in the near future, benefiting more patients.
About Delian Capital:
Delian Capital, founded in 2011, has always focused on technology and innovative healthcare sectors. It primarily targets early-stage technological innovation projects, covering sub-sectors such as semiconductors, intelligent equipment, cloud-native, new therapies, and IBAT. It has invested in over a hundred projects, including: Yesight, De Yi Microelectronics, Xin Zhou Technology, Nanjing Hongtai, Yingchuang Huizhi, Loxo Technology, Mech-Mind Robotics, Fit2Cloud, Venus Medtech, Sanbo Brain Hospital, Amunix, HiFiBiO, ZhiShanWeiXin, ChenAn Biotech, etc.
About Boxing Capital:
Boxing Capital is a venture capital firm focused on early-stage healthcare investments, founded by partners with extensive experience in the medical industry. Currently managing 2 billion RMB in funds, it has invested in over 40 innovative medical device and healthcare service companies with significant market potential. Many of these companies have grown into leaders in their respective niche markets, and several projects have successfully gone public or achieved profitable exits. The investors behind Boxing Capital include top-tier fund-of-funds, industrial capital, entrepreneurs in the medical sector, and seasoned investors in China. With in-depth industry research, clear investment logic, and comprehensive post-investment management capabilities, Boxing Capital has gained continuous support from its investors, earned long-term respect from entrepreneurs, and remains committed to being a trusted long-term partner for top professional investors and entrepreneurs in China.
About WinX Capital
WinX Capital is a leading investment bank in China's healthcare sector, headquartered in Beijing and Shanghai, covering over 3,000 active investment institutions and industry groups. It has been awarded the "Top 1 Financial Advisor in the Healthcare Sector for 2022" by First New Voice, the "Top 2 Best Financial Advisor in the Healthcare Sector for 2021-2022" by Qimingpian & Xinsheng Chuangfu, and the "Top 5 Annual Healthcare Financial Advisor of the 2022-2023 Pengcheng Award" by Arterial Network, among many other honors.